Medical devices, healthcare technology and the business of care
DEVICE CATEGORY · SDA

Electrical Tumor Treatment Fields For Non-Small Cell Lung Cancer

Optune Lua concurrent with PD-1/PD-L1 inhibitors or docetaxel is indicated for adult patients with metastatic non-small cell lung cancer who have progressed on or after a platinum-based regimen.

Product / regulatory recordCompanyPathwayDecision dateSource
Optune LuaP230042/S010
Novocure, GmbHPMA supplementOct 26, 2026FDA
Optune LuaP230042/S008
Novocure, GmbHPMA supplementJul 1, 2026FDA
Optune LuaP230042/S007
Novocure, GmbHPMA supplementFeb 25, 2026FDA
Optune LuaP230042/S005
Novocure, GmbHPMA supplementJan 7, 2026FDA
Optune LuaP230042/S004
Novocure, GmbHPMA supplementOct 8, 2025FDA
Optune LuaP230042/S001
Novocure, GmbHPMA supplementAug 12, 2025FDA
Optune LuaP230042
Novocure, GmbHPMA approvalOct 15, 2024FDA
Source information

Follow the FDA links to view the original records.

All device categories